Amisulpride

氨磺必利

Report date: 2023/03/22 17:20:28
NME

Base Information

Drug NameAmisulpride
Drug Alias Name阿米舒必利amisulprida阿咪舒必利amisulprideamisulpridum +[19] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor antagonistsDopamine D3 receptor antagonists
TargetsDopamine D2 receptorDopamine D3 receptor
Therapy Area/IndicationsChemotherapy-induced nausea and vomitingSchizophreniaDepressive Disorder, Major +[7] 
Global Approved IndicationsSchizophreniaPostoperative Nausea and Vomiting
Approved Indications in ChinaSchizophrenia
Original Approved Country/TerritoryFrance
Original Approved Date1986/01/20
Country/TerritoryCzechiaUnited StatesSlovakia +[12] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAcacia Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInstituto Do Cancer Do Estado De São PauloQilu Pharmaceutical(Hainan) Co LtdEagle Pharmaceuticals Inc +[7] 
Inactive CompaniesSanofiBenaroya Research InstituteNational Institute Of Mental Health (Nimh)
Active IndicationsSchizophreniaPostoperative Nausea and VomitingKidney Failure, Chronic
Inactive IndicationsChemotherapy-induced nausea and vomitingDepressive Disorder, MajorBipolar Disorder +[4] 

Other Information

ATC CodeN05AL05
Related LinksWikipediaDrugBankKEGG